Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

MediStem and Superview to Develop Antibodies that Affect Stem Cells

publication date: Oct 1, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
MediStem of San Diego formed a stem cell collaboration with Superview Biotechnology Co., a subsidiary of Yinhuan Holding. The two companies will use MediStem’s proprietary stem cell lines to screen monoclonal antibodies. Their goal will be to assess whether antibodies can modulate the activity of stem cells that already exist in the body. The companies will evaluate various candidates jointly, as well as apply for grants and share research data. More details....

Stock Symbol: (Pink Sheets: MEDS)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...